To strengthen the new governance structure, a change of representative director and directors will take effect on October 1, 2026. Mr. Kuniharu Imagawa will assume the role of Representative Director and President, while Mr. Yasuhiro Nagahuku will serve as Representative Director and Senior Vice President in charge of the Pharmaceuticals business. The delegation of President duties will be terminated as of September 30, 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7459","jir_company_name":"Medipal Holdings Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-08","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/7459-20260908-01.pdf","jir_short_summary":"To strengthen the new governance structure, a change of representative director and directors will take effect on October 1, 2026. Mr. Kuniharu Imagawa will assume the role of Representative Director and President, while Mr. Yasuhiro Nagahuku will serve as Representative Director and Senior Vice President in charge of the Pharmaceuticals business. The delegation of President duties will be terminated as of September 30, 2026.","jir_summary":"### Section Heading\nThis notice centers on personnel announcements for the new management structure, focusing on changes of representative directors and directors. Mr. Kuniharu Imagawa will assume the position of Representative Director and President, leveraging his management experience and oversight of the Pharmaceuticals business to drive the group's growth strategy. Mr. Shuichi Watanabe will continue in the role of Chairman and oversee group compliance, aiming to stabilize the current structure and strengthen governance. Mr. Yasuhiko Nagahuku will be in charge of the Pharmaceuticals business as Vice President while maintaining the post of Representative Director and Vice President.\n\n### Section 2 Heading\nA biography of the new Representative Director and President is provided in a separate document; since joining the company in 1984, Mr. Imagawa has held key positions within the group. With the formal three-person leadership in effect from October 1, 2026, the group\u2019s oversight structure, including the Pharmaceuticals business, will be strengthened. The delegation of President duties is scheduled to be completed by September 30, 2026.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#NoShareRepurchases, #NotAnExecutiveMove, #ExecutiveAnnouncement","jir_key_figures":"New Representative Director and President: Kuniharu Imagawa (see bio)\nDate of change of Representative Directors: October 1, 2026\nDate of termination of President duties delegation: September 30, 2026","jir_meta_title":"[Medipal Holdings Group] Notice of Changes in Representative Director and Directors | October 2026","jir_meta_description":"Official announcement regarding Medipal Holdings' officer appointments. Appointment of new Representative Director and President Kuniharu Imagawa, role changes for Representative Director and Chairman Shuichi Watanabe, and the Vice President structure under Nagahuku. Also notes the date of completion for the delegation of President duties.","jir_og_title":"[Medipal Holdings] Notice of Executive Appointments","jir_og_description":"Mr. Kuniharu Imagawa appointed as new Representative Director and President. Reports on role changes for the Representative Director and Chairman and the date for lifting the President duties delegation.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7774,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-111543","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n